The queen of hyaluronic acid took 280 million in half a year, and the university teacher became the richest woman

Recently, there is really no story to tell in the beauty industry, from the skin to the nails, everything that needs to be said, and many products have begun to focus on the concept of "recombinant collagen". After the queen of hyaluronic acid and the queen of recombinant collagen, who will be the next female boss to make women's money in the A-share market?

Text丨Financial gossip female author: Wu Yanzu is fake and serious

· · ·

Recently, listed companies have intensively released "report cards".

From the course of "gross profit margin" alone, the "super scholar" is, of course, Moutai, and only a stubborn man in consumption can quietly pry open their wallets.

Women's consumption lists are varied, just about beauty, there are hyaluronic acid sellers, recombinant protein manufacturers, botulinum toxin sellers, injections, and face dresses...... Coincidentally, there is mostly a female boss standing behind them.

Women don't have to embarrass women, but when it comes to making their money, they must be steady and ruthless.

1.

/ "Women's Moutai" is too simple to make money,

The female boss receives 280 million red envelopes a year /

The A-share listed company Aimeike has a resounding nickname called "Women's Moutai".

At present, the company's main products are gel injection products, solution injection products and facial implant products.

To put it bluntly, what makes the mouth fuller, makes wrinkles disappear, and makes the bridge of the nose higher are gels, botulinum toxin, children's face injections, and whitening injections are solutions, in short, they are things that make women whiter and more beautiful.

If you think about these products, in medical aesthetics, people say how much they want, and customers don't dare to bargain. Therefore, the consumer's money is reflected in the financial report, which is called a drift~~ bright.

According to the 2023 annual report, Aimeike's annual operating income was 2.869 billion yuan, a year-on-year increase of 47.99%, and the net profit attributable to shareholders of listed companies was 1.858 billion yuan, a year-on-year increase of 47.08%.

The company's gross profit margin is 73.61%, which is already amazing. However, this gross profit margin is averaged, specific to individual products, such as the gross profit margin of its solution injection products in 2023 is 94.48%, and the gross profit margin of gel injection products will reach 97.49%.

According to the gross profit margin of individual products, Moutai has to be renamed "Men's Aimeike".

It's too easy to earn money and too much, what can I do?

According to the 2023 semi-annual report, Aimeike will distribute a cash dividend of 23.23 yuan (tax included) to shareholders for every 10 shares in the form of transfer shares, totaling 499 million. In addition, Aimeike also distributed a dividend of 1.85 yuan per share to shareholders, totaling 400 million yuan.

That is to say, just over half of 2023, Aimeike's total cash dividends will reach 899 million yuan.

Among them, the biggest beneficiary is the company's chairman Jian Jun, who is the largest shareholder, with a shareholding ratio of 31.05%. In 2023, Jian Jun will win a cash dividend of 280 million yuan.

In 1985, after Jian Jun received a master's degree in business administration from Tsinghua University, he served the iron rice bowl of "COFCO". In the 90s, I followed the trend and quit my job to work for a trading company in the United States, during which I changed several jobs and stayed in the United States for 13 years.

In 2004, the foreign medical cosmetology industry was relatively mature, and Jian Jun saw that rich people in the mainland still needed to go to Hong Kong to do medical cosmetology, so he decisively resigned and returned to China to start a business, aiming at this group of rich women.

Prior to this, her husband had already laid the foundation, and he and his friends established the "Yingzhihuang Biotechnology" company (later renamed Aimeike), with a registered capital of 1.5 million yuan, acting as an agent for beauty products. After Jian Jun went to the company, he served as deputy general manager.

After 5 years of investment, in October 2009, Aimeike successfully developed the first hyaluronic acid product in China. In 2010, the company began to sell goods, and the company moved to the Shimao Building in Beijing, and most of the company's equity fell into the hands of Jian Jun.

In 2012, Aimeike launched the long-acting hyaluronic acid injection product "Baonida", in 2015, Aimeike launched the painless hyaluronic acid injection product "Evelai", and later launched the world's first composite injection material for correcting moderate to severe wrinkles in the neck.

At that time, there were very few similar domestic products on the market, and these three products could be regarded as preserving the glory and wealth of Jian Jun, and she was called the "Queen of Hyaluronic Acid".

Aimeike was listed on September 28, 2020 with an issue price of 118.27 yuan, and the stock price has soared sharply since its listing, and it has broken through the 1,000 yuan mark in early February 2021, becoming the third A-share stock with a stock price of more than 1,000 yuan.

According to the "2023 Hurun Global Self-Made Women Entrepreneurs List" released by the Hurun Research Institute, Jian Jun's wealth has reached 52.5 billion yuan, and her wealth is still growing.

In the catalog of the State Food and Drug Administration, hyaluronic acid, which is not a drug or an injection, belongs to the "third class of medical devices". By the end of 2023, there will be a total of 9 medical device registration certificates.

In order to make more money, oh no, in order to develop new products, Aimeike plans to introduce new projects. The 2023 annual report disclosed that the company's liraglutide injection has completed phase I clinical trials, which are used for "weight management".

The annual report also said that botulinum toxin type A for injection to improve glabellar lines is in the registration stage. In 2021, Aimeike acquired part of the shares of Huons Bio, a South Korean botulinum toxin company, at a premium of 74 times.

In the future, only Qiubo has no wrinkles between the woman's eyebrows, and she can lose weight with one injection, thinking about the sound of gold coins falling to the ground.

2.

/ The stock price fell by 80%,

Young people abandoned the "Queen of Hyaluronic Acid"?/

In the field of A-share listed companies, there are two companies known as "medical beauty duo", one is Aimeike, and the other is Bloomage Biotech. There are also two "hyaluronic acid queens" in A-shares, one is Jian Jun of Aimeike, and the other is Zhao Yan of Bloomage Biotech.

Bloomage Biotech's hyaluronic acid became even more famous than Aimeike. According to the performance report released at the end of February, the company achieved operating income of 6.081 billion yuan, a year-on-year decrease of 4.37%, and net profit attributable to the parent company of 587 million yuan, a year-on-year decrease of 39.5%. This is also the first time since its listing in 2019 that Bloomage Biotech has experienced a decline in annual revenue and net profit at the same time.

The express report mentions a decline in gross profit margin, but there is no specific figure. However, the market analysis should not be too bad, according to the 2023 interim report, the gross profit margin of its functional skin care products reached 74.49%.

There has been a long warning of Bloomage Biotech's decline in revenue. During the Double 11 period in 2023, the total GMV of Bloomage Biotech's four major brands (Runbaiyan, Quadi, BM Muscle Active, and Mirepair) on Tmall flagship store + Douyin decreased by 36% year-on-year.

According to the semi-annual report, in the first half of 2023, Runbaiyan achieved revenue of 632 million yuan, down 2.04% year-on-year, Quadi achieved revenue of 543 million yuan, down 10.1% year-on-year, and Mirepair achieved revenue of 217 million yuan, down 16.81% year-on-year; BM's muscle activity revenue was 341 million yuan, a year-on-year decrease of 29.62%.

The boss of Bloomage Biotech is called Zhao Yan, and the public called her "Queen of Hyaluronic Acid" before Jian Jun. In November 2022, Eighth Sister introduced Zhao Yan in the article "Using 210 million to pry 880 million employees, worth 44 billion "hyaluronic acid queen" is short of this money?".

At that time, the former employees of Bloomage Biotech reported to the regulatory authorities that Chairman Zhao Yan was threatened with work and livelihood, embezzled the interests of minority shareholders, and "forced" to recover 880 million yuan worth of employees' shares at a low price of 210 million yuan before and after Bloomage Biotech's IPO.

Zhao Yan, 58, was born in Kunming, Yunnan Province in 1966 to an intellectual family, and she studied biology at East China Normal University and stayed on to teach after graduation.

After resigning, she traveled to Hainan, dumped refrigerators, opened garment factories, and ate meat in the tide of Hainan real estate. At that time, she opened three pieces of land in a garment factory, and the most expensive one was about 3 million yuan per mu when it was sold, and she was completely financially free.

In 2001, when she returned to Beijing for development, Zhao Yan won the "Central World Trade Center", one of the top ten key projects in the CBD of Beijing's central business district. Taking the opportunity of the 2008 Beijing Olympic Games, Zhao Yan also undertook the Olympic basketball venue Wukesong Gymnasium, where stars such as Jacky Cheung recently gathered to sing.

In addition, since 2011, Zhao Yan has invested another 400 million yuan to build the "Bloomage LIVE Wukesong" sports service complex around Wukesong Gymnasium, covering a total area of about 1,000 acres.

While doing real estate, Zhao Yan is in contact with medical aesthetic projects. Through several equity acquisitions, Zhao Yan obtained all the shares of Freda Biotech and changed its name to Bloomage Biotech.

In 2001, Bloomage Biotech turned losses into profits and achieved a profit of 3 million, in 2005, the company became a world-renowned supplier of hyaluronic acid, and in 2008, the company was listed on the Hong Kong stock market.

In 2017, Zhao Yan decided to delist from the Hong Kong stock market. Then in 2019, it landed on the Science and Technology Innovation Board.

Because of stepping on the right outlet, Bloomage Biotech experienced a round of soaring market in 2021, with the highest share price reaching 313.48 yuan per share on July 5, 2021, and the market value reaching 151.1 billion yuan. Zhao Yan gained fame and fortune and became the richest man on the Science and Technology Innovation Board.

A few years ago, the media reported that the cost of a thousand-yuan hyaluronic acid is only 19 yuan, and there is a saying that the cost of hyaluronic acid worth 5,000 yuan is only 20 yuan. Therefore, Bloomage Biotech's gross profit margin has been stable at about 77% all year round, and once even exceeded 80% or even 90%.

After the peak, there is a lot of ups and downs. At present, the share price of Bloomage Biotech has fallen to 56 yuan per share, the stock price has fallen by about 80% from the peak, and the market value has evaporated by 100 billion.

The media also reported that in recent years, young people have become somewhat desensitized to the heat of hyaluronic acid. The reason is self-explanatory, hyaluronic acid is sold expensively, but in reality, how many people have been reborn from ugly ducklings to shining white swans through hyaluronic acid?

The medical aesthetic industry has to tell another story. Aimeike thinks this more thoroughly than Bloomage Biotech, Aimeike not only produces hyaluronic acid, but also a variety of products that pinch women are clearly reflected in the financial report, which gives investors more room for imagination.

Zhao Yan also understands the importance of product diversity, and in the first two years she claimed to make "collagen", but the splash was not big. At present, there are already strong competitors in this field, and everyone's collagen has cultivated a richest woman.

3.

/ A university teacher turned into the richest woman in Shanxi,

With 15 years of the company's listing, L'Oreal came to her house to sweep the goods /

On March 25, the Hurun Research Institute released the "2024 Hurun Global Rich List", and the richest woman in Shanxi is Yang Xia, whose personal wealth is currently as high as 8.5 billion.

Yang Xia's money mainly comes from the A-share listed company "Jinbo Biotechnology", which is the first listed company in China to focus on "recombinant collagen". Some promotional materials say that this thing can be DNA recombinant and can also be repaired (I don't know if it's true or not)......

Have you ever heard of L'Oreal's "Little Honey Pot", the core ingredient in it is this recombinant collagen, and it uses Jinbo Bio's products, and the two parties have established a strategic partnership in 2023. In addition, several domestic cosmetics giants also buy products from the company.

Jinbo Biotech's 2023 annual report shows that its gross profit margin is "only" 43.85%, which is a "shame" for medical aesthetic raw material companies. Don't worry, look at people's revenue, the revenue in 2023 will be 780 million yuan, a year-on-year increase of 99.96%, and the net profit will be 300 million yuan, a year-on-year increase of 174.6%.

This is the first annual report of Jinbo Biotech after its listing, and it has doubled its revenue and net profit, which shows that it is making more money.

Yang Xia, a native of Qinshui, Shanxi, was born in September 1974 and graduated from Shanxi Medical University with a master's degree in clinical medicine.

In 2008, Yang Xia co-founded Taiyuan Jinbo Biomedical Technology Co., Ltd., the predecessor of Jinbo Biotechnology, based on basic research and industrialization in the field of "functional proteins", and Yang Xia also served as the director of the Shanxi Provincial Key Laboratory of Functional Proteins.

Six years later, in 2014, Jinbo Biotech successfully developed the world's first recombinant type III collagen product, becoming a dark horse in the field of biomedicine, and thus establishing its position in the medical beauty industry.

In 2015, Yang Xia led Jinbo Biotech to be listed on the New Third Board. In the second year, Yang Xia planned to hit A-shares again. After giving up the Shanghai Stock Exchange, he entered the Beijing Stock Exchange in December 2021 for listing counseling, was accepted in June 2022, and successfully "passed" in March 2023.

On July 20, 2023, Jinbo Biotech was successfully listed on the Beijing Stock Exchange, known as the "first stock" of recombinant collagen. From a university teacher to the owner of a listed company, Yang Xia only took 15 years.

Because of the scarcity of themes, Jinbo Bio's shares have been sought after by investors since their listing, and the stock price broke through the 100 yuan mark on the first day of listing, with the highest price reaching 302.33 yuan per share, making it the "first high-priced stock" on the Beijing Stock Exchange for a long time. At present, the share price of progressive biology is 220 yuan per share, with a market value of more than 15 billion yuan.

Jinbo Biotech's R&D expenses in 2023 will be 104 million, and the R&D rate will be 13.28%. At present, the company has obtained 50 invention patents.

Yang Xia is right to do this, products such as recombinant proteins have not yet been marketed on a large scale, and after R&D "rolls up" other companies, this big cake is its own. The medical beauty industry is like this, developing something new, coupled with the help of beauty companies, the stock price can't be stopped when the time comes.

Recently, there is really no story to tell in the beauty industry, from the skin to the nails, everything that needs to be said, and many products have begun to focus on the concept of "recombinant collagen".

In January this year, L'Oreal released the second generation of small honeypots, saying what "directly replenishing collagen, reshaping the original elasticity, tenderness and brightness".

Therefore, domestic brands such as Han Shu and Proya also have to follow the concept of recombinant collagen.

Of course, you will recombine, maybe someone else will recombine, there is a high possibility.

There is a theory of "business cycle" in economics, and business activities will have cyclical problems, which are generally divided into four stages: boom, recession, bust and recovery.

To put it bluntly, there are talented people from generation to generation, each leading the way for hundreds of years.

After the queen of hyaluronic acid and the queen of recombinant collagen, who will be the next female boss to make women's money in the A-share market?